Tetra Bio-Pharma

Clinical Pipeline

QIXLEEF and CAUMZ

  • Chronic pain product with rapid relief, safer profile and less abuse potential compared to opioids or other pain drugs
  • Novel Product with a unique patented inhalation device that achieves delivered-dose uniformity which exceeds FDA thresholds
  • $90mm spent to date

REDUVO & REDUVO ADVERSA

  • REDUVO is a Synthetic THC soft-gel capsule requiring only a single Phase 1 study for NDS submission with Health Canada
  • REDUVO ADVERSA is Administered using a THC-based mucoadhesive, delivering sustained release of dronabinol
  • Both drugs quality for fast approval pathways (i.e. 505(b)(2) or a single phase 1 trial.

ARDS-003

  • NIH validated clinical results show central and peripheral reduction of Cytokine Release Syndrome (CRS)
  • Targets immune cells involved in systemic hyperinflammatory response
  • Avoids side effects associated with steroids

Building a Better Tomorrow

Tetra Aims to Build a Better Tomorrow by Addressing Unmet Medical Needs in Pain, Inflammation, Ophthalmology, and Oncology.